Maxygen (MAXY) Shares Rise Amid Final Rejection of All Claims of Amgen '804 Patent
Maxygen (Nasdaq: MAXY) shares are on the move after hours following news the US PTO has issued a Right of Appeal Notice in the inter parties reexamination proceeding for Amgen's (Nasdaq: AMGN) US Pat. No. 7,381,804 that includes a final rejection of all claims in the '804 patent.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Syngenta (SYT) settles atrazine litigation; will pay $105M in deal
- Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
- SEC staff said to end Lehman probe without recommending action
Create E-mail Alert Related Categories
Corporate News, LitigationSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
